Clinical Research Services

The combination of the MHRA Accreditation and the expert knowledge of conducting 500 Early Phase Studies ensure Richmond Pharmacology can provide you with a service that meets your needs.

Adaptive Phase I Studies

Rapid approval, flexible conduct, adaptive protocols in a MHRA accredited facility.

View service

TQT Studies

World-class specialist clinic and core laboratory all under one roof.

View service

Bridiging Studies

International specialist provider of Japanese Bridging Studies since 2002.

View service

Patient Recruitment

Fast and efficient in-house team, specialising in patient recruitment

View service

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more